Compare Organon & Co. Common Stock (OGN) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs PAGSEG Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while PAGSEG Inc trades at $10.83 (market cap $3.03B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and PAGSEG Inc pays the higher dividend (10.19%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and PAGSEG Inc for 27 Days on average.
| OGN | PAGS | |
|---|---|---|
Market Cap | $3.62B | $3.03B |
Volume | 2,892,999 | 2,770,540 |
Sector | Health | Industrials |
52-Week High | $13.81 | $12.00 |
52-Week Low | $5.70 | $8.44 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $11.04B | $11.16B |
Dividend Yield | 0.58% | 10.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
PAGS trades at $10.99, down 1.35% on the day, with a bullish technical signal from moving averages but overbought short-term RSI readings. The company reported a Q2 2026 EPS beat of $0.41 vs. $0.389 expected, with revenue growth to $20.6B in 2026 and a net income margin of 10.45%. A dividend of $0.28 is scheduled for payment on September 30, 2026.
The stock presents a value opportunity with low P/E (7.31) and P/S (0.76) ratios, supported by strong analyst consensus (62.5% buy ratings) and a $10.70 price target. Key risks include macroeconomic pressures in Brazil and elevated credit losses, but robust cash flow and banking growth underpin long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
